All In Biotech

Drug Trial Radar · NCT04419506

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally

Last checked: Nov 19, 2026Latest source record: Nov 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Jul 28, 2020

Primary completion

Oct 6, 2021

Study completion Oct 15, 2021

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study. The purpose of the study is to find out whether a medicine called BI 1015550 can slow down the worsening of lung function. Participants are in the study for about 4 months. During this time, they visit the study site about 7 times. At the beginning, they visit the study site every 2 weeks. After 1 month of treatment, they visit the study site every 4 weeks. The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The participants take BI 1015550 or placebo tablets twice a day. The participants have lung function tests at study visits. The results of the lung function tests are compared between the BI 1015550 group and the placebo group. The doctors also regularly check the general health of the participants.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • BI 1015550Drug

    18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.

  • PlaceboDrug

    placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change From Baseline in Forced Vital Capacity (FVC) at 12 WeeksTime frame: Baseline (day 1) and week 12.

Locations

75 sites in 22 countries. Site status is shown where the registry gives one.

  • St. Francis Medical Institute

    Clearwater, Florida

  • University of Florida

    Gainesville, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • The Lung Research Center, LLC

    Chesterfield, Missouri

  • Creighton University

    Omaha, Nebraska

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Diagnostics Research Group

    San Antonio, Texas

  • University of Utah Health Sciences Center

    Salt Lake City, Utah

  • Centro de Investigaciones Metabólicas (CINME)

    C.a.b.a, Argentina

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • LKH-Univ. Hospital Graz

    Graz, Austria

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Dr. Georges-L.-Dumont University Hospital Centre

    Moncton, New Brunswick, Canada

  • Queen's University

    Kingston, Ontario, Canada

  • Dr. Syed Anees Medicine Professional Corporation

    Windsor, Ontario, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada

  • Instituto Nacional del Tórax

    Providencia, Santiago de Chile, Chile

  • Centro de Investigación del Maule

    Talca, Chile

  • Peking Union Medical College Hospital

    Beijing, China

  • The Second Hospital of Jilin University

    Changchun, China

  • West China Hospital

    Chengdu, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • University Hospital Na Bulovce, Prague

    Prague, Czechia

  • University Thomayer's Hospital

    Praha 4 - Krc, Czechia

  • Aarhus University Hospital

    Aarhus N, Denmark

  • Herlev and Gentofte Hospital

    Hellerup, Denmark

  • Odense University Hospital

    Odense C, Denmark

  • HYKS Keuhkosairauksien tutkimusyksikkö

    Helsinki, Finland

  • KYS, Keuhkosairauksien

    Kuopio, Finland

  • Oulun yliopistollinen keskussairaala

    Oulu, Finland

  • Tampere University Hospital

    Tampere, Finland

  • TYKS

    Turku, Finland

  • Fachkrankenhaus Coswig GmbH

    Coswig, Germany

  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

    Essen, Germany

  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Lungenfachklinik Immenhausen

    Immenhausen, Germany

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.